Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting glucagon / GIP / GLP-1 triple receptor agonist
An experimental drug being studied for fatty-liver disease and weight-related health problems.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
A randomized 12-week Phase 1b/2a NAFLD study reported dose-dependent liver-fat and weight signals in up to 60 participants.
It shares receptor labels with retatrutide but not molecular design, receptor balance, or evidence.
The highest group reached an 88% reduction in the sponsor poster.
Placebo-corrected mean weight change reached about 5.1% at 12 weeks.
Two early-study cases resolved after treatment discontinuation.
No outcomes were publicly available at the cutoff.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational — early MASH-focused human development Biopsy-confirmed Phase 2 efficacy, fibrosis and clinical liver outcomes, glycemic tradeoffs from glucagon agonism, long-term safety, weight durability, and comparative performance.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Findings presented at a conference. Read the source’s stated limits; a full peer-reviewed paper may not yet be available.
A sponsor-hosted EASL 2020 poster describes a randomized Phase 1b/2a study in adults with obesity and fatty liver without diabetes.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 12 weeks | 0.01, 0.02, 0.04, 0.06, or 0.08 mg/kg groups | Once weekly |
These are separate weight-based cohorts, not fixed milligram doses or one escalation sequence. A conference poster provides less detail and scrutiny than a complete peer-reviewed results paper.
Hanmi · HM15211 EASL 2020 clinical poster Abstract, study design, and dose-cohort tablesThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Peer-reviewed and official records describe a biopsy-based trial in adults with MASH and fibrosis, but Relay's verified record does not contain a complete peer-reviewed efficacy report from that program.
Population: Adults with biopsy-confirmed MASH and fibrosis
Design: Peer-reviewed description of a randomized biopsy-confirmed MASH trial
Mechanisms
Efocipegtrutide is an Fc-linked, long-acting triple agonist targeting glucagon, GIP, and GLP-1 receptors. In a sponsor-presented 12-week Phase 1b/2a study of adults with obesity and NAFLD, dose-dependent liver-fat reductions reached 88% in the highest group and placebo-corrected weight reduction reached about 5.1%. Mild gastrointestinal events were common, and two hyperglycemia cases resolved after discontinuation. A biopsy-confirmed MASH Phase 2b program was designed to evaluate histologic endpoints, but public completed efficacy results were not located at the cutoff. Fast-track and orphan designations indicate development interest, not approval.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Phase 1b/2a signals and a biopsy-based Phase 2 program.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The main efficacy signal comes from a small sponsor poster.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A trial-design paper explains what researchers planned to measure; it does not show that the intervention worked. Sponsor-poster findings are kept separate from independently reviewed outcomes, and no generic-vial preparation claim is supported. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Peer-reviewed description of a randomized biopsy-confirmed MASH trial
Adults with biopsy-confirmed MASH and fibrosis
The design targets histologic endpoints needed to move beyond imaging-only liver-fat changes.
Study administration: Weekly efocipegtrutide dose groups or placebo
Limitations: A design paper contains no efficacy result.
Randomized, double-blind, placebo-controlled trial registry
Adults with biopsy-confirmed MASH
The registry confirms the intended biopsy-based Phase 2 program.
Study administration: Weekly HM15211 or placebo
Limitations: No public completed outcomes were located at the cutoff.
Official program description
Investigational development program
The sponsor positions the molecule as an Fc-linked weekly glucagon/GIP/GLP-1 triple agonist.
Study administration: Long-acting triple-receptor agonism
Limitations: Sponsor mechanism and design descriptions do not establish efficacy.
Randomized, placebo-controlled dose-ranging study
Adults with obesity and nonalcoholic fatty liver disease
The sponsor poster reported dose-dependent liver-fat reduction up to 88% and placebo-corrected weight reduction up to 5.1%.
Study administration: Once-weekly subcutaneous HM15211 dose groups or placebo
Limitations: Small, short sponsor-poster evidence is preliminary and not a clinical liver-outcomes result.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2023-04-01 · PMID 37028504 · DOI 10.1016/j.cct.2023.107095
2020-08-01 · NCT04505436
2020-08-01